drugset / Trial / NCT05015972
UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies
Phase 0
Withdrawn
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Nanjing Bioheng Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm, open-label, single-center prospective study to determinethe safety and efficacy of CTA30X UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B Hematologic Malignancies
Timeline
- Start
- 2021-08-20
- Primary completion
- 2023-06-30
- Completion
- 2023-12-31
Outcome
Outcome not reported
Stopped: “No proper participant is found.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CTA30X UCAR-T | Cell therapy | — | Intravenous |